Premium
Anti‐VEGF for the treatment of CNV secondary to angiod streaks
Author(s) -
ROUVAS A
Publication year - 2011
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2011.3115.x
Subject(s) - angioid streaks , ranibizumab , medicine , choroidal neovascularization , ophthalmology , bevacizumab , visual acuity , aflibercept , surgery , chemotherapy
Purpose The purpose of this report is to evaluate the safety and efficacy of intravitreal antivascular endothelial growth factors (anti‐VEGF) in eyes with macular choroidal neovascularization ( CNV) secondary to angioid streaks. Methods From the present evidence in the literature it may be concluded that anti‐VEGF therapy with ranibizumab or bevacizumab, based on the strategy to 'according to need' , is beneficial for the treatment of CNV secondary to angioid streaks. Results Visual acuity can be maintained or even improved over a prolonged period of time, even with a low number of injections, at high rates ranging from 85.7 to 100% , especially in the early stages of the disease. Later when more widespread atrophic changes of pigment epithelium have occurred ,especially if they related the foveola, the visual prognosis was not favorable. Although at present there are not definite proofs with safety problems of anti‐VEGF agents in the treatment of CNV secondary to angioid streaks, patients need to be aware of the off‐label nature of the treatment with anti‐VEGF.. Conclusion Overall, based on the evidence available, intravitreal treatment with anti‐VEGF seems to be the best choice at present to treat patients with CNV secondary to angioid streaks .